Loading...
Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine
Hamidi, Ahd Hoeksema, Femke Velthof, Pim Lemckert, Angelique Gillissen, Gert Luitjens, Alfred Bines, Julie E. Pullagurla, Swathi R. Kumar, Prashant Volkin, David B.
Hamidi, Ahd
Hoeksema, Femke
Velthof, Pim
Lemckert, Angelique
Gillissen, Gert
Luitjens, Alfred
Bines, Julie E.
Pullagurla, Swathi R.
Kumar, Prashant
Volkin, David B.
Citations
Altmetric:
Abstract
Despite solid evidence of the success of rotavirus vaccines in saving children from fatal gastroenteritis, more than 82 million infants worldwide still lack access to a rotavirus vaccine. The main barriers to global rotavirus vaccine coverage include cost, manufacturing capacity and suboptimal efficacy in low- and lower-middle income countries. One vaccine candidate with the potential to address the latter is based on the novel, naturally attenuated RV3 strain of rotavirus, RV3-BB vaccine administered in a birth dose strategy had a vaccine efficacy against severe rotavirus gastroenteritis of 94% at 12 months of age in infants in Indonesia. To further develop this vaccine candidate, a well-documented and low-cost manufacturing process is required. A target fully loaded cost of goods (COGs) of ≤$3.50 per course of three doses was set based on predicted market requirements. COGs modelling was leveraged to develop a process using Vero cells in cell factories reaching high titers, reducing or replacing expensive reagents and shortening process time to maximise output. Stable candidate liquid formulations were developed allowing two-year storage at 2–8 °C. In addition, the formulation potentially renders needless the pretreatment of vaccinees with antacid to ensure adequate gastric acid neutralization for routine oral vaccination. As a result, the formulation allows small volume dosing and reduction of supply chain costs. A dose ranging study is currently underway in Malawi that will inform the final clinical dose required. At a clinical dose of ≤6.3 log10 FFU, the COGs target of ≤$3.50 per three dose course was met. At a clinical dose of 6.5 log10 FFU, the final manufacturing process resulted in a COGs that is substantially lower than the current average market price, 2.44 USD per dose. The manufacturing and formulation processes were transferred to BioFarma in Indonesia to enable future RV3-BB vaccine production.
Description
Date
2021-04-08
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Collections
Research Projects
Organizational Units
Journal Issue
Keywords
Oral rotavirus vaccine, Fixed bed bioreactor, Manufacturing process, Cost-of-goods modelling, Stable liquid formulation
Citation
Hamidi, A., Hoeksema, F., Velthof, P., Lemckert, A., Gillissen, G., Luitjens, A., Bines, J. E., Pullagurla, S. R., Kumar, P., Volkin, D. B., Joshi, S. B., Havenga, M., Bakker, W., & Yallop, C. (2021). Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine. Vaccine, 39(15), 2048–2059. https://doi.org/10.1016/j.vaccine.2021.03.033